New AI Tool Expands Patient Reach and Market Opportunities
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The newly developed algorithm utilizes heart rate and heart rate variability to accurately screen for Major Depressive Episode using a single lead ECG. Initial testing on a subset of subjects has shown promising performance metrics, indicating high sensitivity and specificity for the screening tool. The company plans to pursue further clinical trials and licensing opportunities to enhance the algorithm's application in various markets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from TrivarX
- September 2024 Quarterly Activities Report and Appendix 4C
- June 2024 Quarterly Activities Report and Appendix 4C
- Positive Results from Phase 2 SAMDE Study
- TrivarX Receives Firm Commitments to Raise $2.5 million
- March 2024 Quarterly Activities Report and Appendix 4C
Later from TrivarX
- TrivarX Receives $1.03m R&D Tax Incentive
- December 2024 Quarterly Activities Report and Appendix 4C
- Appendix 4D & Half-Year Financial Report to 31 December 2024
- Trial with US Department of Veterans Affairs
- TrivarX Receives Firm Commitments to Raise $2.25 million
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX